| Target ID: | dt892 |
|---|---|
| CID: | 6445781 |
| Compound Name: | Cp-461 |
| Gene ID: | 595 |
| Gene Name: | CCND1 |
| Species: | Homo sapiens (human) |
| PubMed IDs: | 15475462 |
| Action: | (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride promotes the reaction [3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid results in decreased expression of CCND1 mrna]|(5-fluoro-2-methyl-1-(4-pyridyl)methylen |
Knowledge Graph
| Target ID | CID | Compound Name | Gene ID | Gene Name | Species | Action | |
|---|---|---|---|---|---|---|---|
| dt401 | 5961 | Glutamine | 595 | CCND1 | Homo sapiens (human) | Glutamine deficiency inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] | Details |
| dt432 | 8378 | Framycetin | 595 | CCND1 | Homo sapiens (human) | Agonist | Details |
| dt725 | 5280483 | Vitamin K | 595 | CCND1 | Rattus norvegicus (Norway rat) | Quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of CCND1 mrna]|[warfarin co-treated with vitamin K] results in increased expression of CCND1 mRNA | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| Drug104 | CP-461 | Chemical drug | -- | -- | -- | Under clinical trials | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Mechanism | |
|---|---|---|---|---|
| No data available | ||||
| Strategy ID | Therapy Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||